More than two dozen Massachusetts companies have announced plans to create vaccines, treatments or devices for COVID-19 — garnering attention from investors but raising questions about long-term success.
Atlas Venture Partner Kevin Bitterman said during a virtual LabCentral discussion Tuesday that it would be “almost criminal” for venture capital firms and their portfolio companies not to consider turning their attention to the development of COVID-19 products. His firm is encouraging its startups to consider development of preventative or therapeutic drugs.
That sentiment is trickling down through the public and private markets.
Copyright Boston Business Journal
